{"id":"e0cace3e-b4ea-59d1-8001-dc5262404385","stable_key":"182336c6-ed36-5ec6-8a09-25c31096262e:dim-i3c-ratio","predicate":"increases","statement":"I3C increased the urinary 2-to-16-alpha-hydroxyestrone ratio without significant changes in the reported serum hormones.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"c4ff5540-be31-5db0-95e7-b559b4f18dc0","mechanism_event_label":"Changing metabolite proportions is different from lowering every circulating hormone.","subject":{"id":"0e7ccfc7-b9a1-53e0-88f4-a061579ad94d","slug":"indole-3-carbinol","display_name":"Indole-3-carbinol / I3C","entity_type_key":"small_molecule"},"object":{"id":"3973614c-dc93-5138-b444-175dd134b878","slug":"urinary-2-to-16-hydroxyestrone-ratio","display_name":"Urinary 2-hydroxyestrone to 16-alpha-hydroxyestrone ratio","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"c4ff5540-be31-5db0-95e7-b559b4f18dc0","stable_key":"182336c6-ed36-5ec6-8a09-25c31096262e:dim-i3c-ratio-event","event_type":"observed_intervention","label":"Changing metabolite proportions is different from lowering every circulating hormone.","description":"I3C increased the urinary 2-to-16-alpha-hydroxyestrone ratio without significant changes in the reported serum hormones.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"0e7ccfc7-b9a1-53e0-88f4-a061579ad94d","slug":"indole-3-carbinol","display_name":"Indole-3-carbinol / I3C","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"3973614c-dc93-5138-b444-175dd134b878","slug":"urinary-2-to-16-hydroxyestrone-ratio","display_name":"Urinary 2-hydroxyestrone to 16-alpha-hydroxyestrone ratio","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/dim-research/16103443.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"ece0ac1a0c31053cdc1ec3eefbf9c78887018e0eddf2db36c3a1a07c998e15c4\", \"start_char\": 0, \"end_char\": 1706, \"text_sha256\": \"ece0ac1a0c31053cdc1ec3eefbf9c78887018e0eddf2db36c3a1a07c998e15c4\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Phase I placebo run-in and dose escalation","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"I3C 400 mg/day then 800 mg/day for four weeks each","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"The administered compound was I3C, not DIM. Multiple acid-condensation products and nonrandomized sequential periods prevent assigning the observed fold change specifically to DIM.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Diindolylmethane (DIM) research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"dim","display_name":"3,3'-Diindolylmethane / DIM","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"17 women at elevated breast-cancer risk","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Changing metabolite proportions is different from lowering every circulating hormone.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[dim-p16103443] A phase I study of indole-3-carbinol in women: tolerability and effects. (2005). https://pubmed.ncbi.nlm.nih.gov/16103443/ DOI: 10.1158/1055-9965.epi-05-0121","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Caffeine CYP1A2 phenotype and estrogen metabolites","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"dfcf3f00-20fd-5694-9416-f785aa1b6cdb","evidence_kind":"source_excerpt","locator":"Lines 1039-1050","start_line":1039,"end_line":1050,"excerpt":"### dim-i3c-ratio\nI3C increased the urinary 2-to-16-alpha-hydroxyestrone ratio without significant changes in the reported serum hormones.\nCondition category: normal\nnutrient_topic: Diindolylmethane (DIM) research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: Changing metabolite proportions is different from lowering every circulating hormone.\norganism: 17 women at elevated breast-cancer risk\ntissue_or_cell_type: Caffeine CYP1A2 phenotype and estrogen metabolites\nexperimental_model: Phase I placebo run-in and dose escalation\nlimitations: The administered compound was I3C, not DIM. Multiple acid-condensation products and nonrandomized sequential periods prevent assigning the observed fold change specifically to DIM.\nexposure: I3C 400 mg/day then 800 mg/day for four weeks each\nevidence_span: {\"source_cache\": \"artifacts/dim-research/16103443.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"ece0ac1a0c31053cdc1ec3eefbf9c78887018e0eddf2db36c3a1a07c998e15c4\", \"start_char\": 0, \"end_char\": 1706, \"text_sha256\": \"ece0ac1a0c31053cdc1ec3eefbf9c78887018e0eddf2db36c3a1a07c998e15c4\"}\n[dim-p16103443] A phase I study of indole-3-carbinol in women: tolerability and effects. (2005). https://pubmed.ncbi.nlm.nih.gov/16103443/ DOI: 10.1158/1055-9965.epi-05-0121","model_system":"Phase I placebo run-in and dose escalation","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [dim-p16103443] A phase I study of indole-3-carbinol in women: tolerability and effects. (2005). https://pubmed.ncbi.nlm.nih.gov/16103443/ DOI: 10.1158/1055-9965.epi-05-0121","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"b6d70682-97f9-5893-a03c-f9f88836033c","stable_key":"import-182336c6-ed36-5ec6-8a09-25c31096262e","title":"Diindolylmethane (DIM): formation, receptor signaling, metabolism and drug interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"31e14060de904976d2f5d439f2bc9c8a99a72d34626c562c78429025e050d404","revision_id":"611094c1-a9cf-5b9b-b255-ac70b571696a","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}